ClinicalTrials.gg
RecruitingNCT07108270Updated Dec 22, 2025

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

A Phase 2 interventional study of Dostarlimab and Carboplatin in Neoplasms, Endometrial, sponsored by GlaxoSmithKline. Recruiting at 1 site in China. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies testing dostarlimab in Endometrial Neoplasms — 12 open to participants now, 17 under way, 3 of them phase 3. dostarlimab · Endometrial Neoplasms.

Planned enrollment
13th of 18
30 · median 46
Started
2025
with 3 others
Phase 2
9 of 18
6 open now
Primary completion
2030-03
later than 12 of 16 live
Registered
15th of 18
by date
Lead sponsor
5 of 18
GlaxoSmithKline

Among the 18 studies testing dostarlimab in Endometrial Neoplasms, this one is the 13th largest by planned enrollment, is one of 4 that started in 2025, is one of 9 in phase 2, reaches primary completion later than 12 of the 16 other live ones, and was the 15th registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

12 of the 18 studies testing dostarlimab in Endometrial Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About dostarlimab

dostarlimab: first FDA approval 2021 (JEMPERLI), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing dostarlimab in Endometrial Neoplasms, or all of them as a file.
02

Study summary

The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.

03

Conditions studied

  • Neoplasms, Endometrial

Keywords

  • Endometrial cancer
  • Dostarlimab
  • Carboplatin
  • Paclitaxel
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has or cytologically proven EC with recurrent or advanced disease.
  2. Participant has molecular subtype of defective mismatch repair (dMMR) or microsatellite instability high (MSI-H) determined by the central reference laboratory before study intervention.
  3. Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination, and presence of at least one target lesion per 1.1 based on Investigator's assessment and meet at least 1 of the following criteria:

    1. Has primary Stage III to IV disease and is naive to systemic anticancer therapy for EC;
    2. Has first recurrent disease and is naïve to systemic anticancer therapy for EC;
    3. Had received prior /adjuvant anticancer therapy and had a recurrence or PD ≥6 months after completing treatment (first recurrence only).
  4. Participant has adequate archive tumor tissue sample for MMR/MSI status testing. If no is available, tissue sample must be obtained before study intervention.
  5. Participant is not pregnant or breastfeeding and agrees to use a highly effective method during the study period if a woman of (WOCBP).
  6. Participant has an Performance status (ECOG PS) of 0 or 1.
  7. Participant has adequate organ function, as assessed by hematologic, renal, hepatic and coagulation parameters.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a concomitant , or participant has a prior non-endometrial invasive malignancy who has been disease-free for \<3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.
  2. Participant has any medical history of interstitial lung disease or pneumonitis.
  3. Participant has cirrhosis or current unstable liver or biliary disease.
  4. Participant has known uncontrolled central nervous system , carcinomatosis meningitis, or both.
  5. Participant has a diagnosis of immunodeficiency.
  6. Participant has received prior therapy with an anti- Programmed death protein 1 (), anti- Programmed death ligand 1 (PD-L1), anti- Programmed death ligand 2 (PD-L2), or anti- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent.
  7. Participant has not recovered adequately from AEs.
  8. Participant has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy, or immunotherapy) within 21 days prior to the first dose of study intervention.
  9. Participant has received any within 30 days of the first dose of study intervention. Vaccination against coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms are not exclusionary.
  10. Participant has surface antigen (HBsAg) positive, or virus (HCV) Ribonucleic acid (RNA) positive at screening or within 3 months prior to the first dose of study intervention.
  11. Participant is known (HIV) infection.
  12. Participant is currently participating and receiving study intervention or has participated in a study of an agent and received study intervention or used an investigational device within 4 weeks of the first dose of treatment.
  13. Participant with to carboplatin and paclitaxel.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Dostarlimab-Carboplatin-Paclitaxel followed by Dostarlimab Monotherapy

    Biological: Dostarlimab · Drug: Carboplatin · Drug: Paclitaxel

Interventions

06

What researchers measure

Primary outcomes

  1. Durable Response Rate for 12 months (DRR12) assessed by Blinded Independent Central Review (BICR)

    DRR12 is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR), and Duration of Response (DOR) lasting greater than or equal to (≥) 12 months, per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).

    Time frame: Up to approximately 148 weeks

Secondary outcomes

  1. DRR12 assessed by Investigator

    DRR12 is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR), and Duration of Response (DOR) lasting greater than or equal to (≥) 12 months, per RECIST 1.1.

    Time frame: Up to approximately 148 weeks

  2. Progression-free survival (PFS) per RECIST 1.1, assessed by BICR

    PFS is defined as the time from the date of first dose to the date of first documented disease progression (PD) or death due to any cause, whichever comes first.

    Time frame: Up to 226 weeks

  3. Progression-free survival (PFS) per RECIST 1.1, assessed by investigator

    PFS is defined as the time from the date of first dose to the date of first documented PD or death due to any cause, whichever comes first.

    Time frame: Up to 226 weeks

  4. Overall survival (OS)

    OS is defined as time from first dose of study intervention to death from any cause.

    Time frame: Up to 226 weeks

  5. Overall response rate (ORR) per RECIST 1.1 assessed by BICR

    ORR is defined as the proportion of participants with confirmed CR or PR.

    Time frame: Up to 226 weeks

  6. ORR per RECIST 1.1 assessed by Investigator

    ORR is defined as the proportion of participants with confirmed CR or PR.

    Time frame: Up to 226 weeks

  7. Duration of response (DOR) per RECIST 1.1 assessed by BICR

    DOR is defined as the time from the date of first documented objective response (confirmed CR or PR) to the date of first documented PD or death due to any cause, whichever comes first.

    Time frame: Up to 226 weeks

  8. DOR per RECIST 1.1 assessed by Investigator

    DOR is defined as the time from the date of first documented objective response (confirmed CR or PR) to the date of first documented PD or death due to any cause, whichever comes first.

    Time frame: Up to 226 weeks

  9. Serum concentration of dostarlimab

    Time frame: Up to 67 weeks

  10. Concentration at the end of infusion (C-EOI) for dostarlimab

    Time frame: Up to 67 weeks

  11. Trough concentration (Ctrough) for dostarlimab

    Time frame: Up to 67 weeks

  12. Number of participants with Anti-drug antibody (ADA) against dostarlimab

    Time frame: Up to 226 weeks

  13. Number of participants with adverse events (AEs), Immune-mediated adverse events (imAEs), and serious adverse events (SAEs) by severity

    Time frame: Up to 226 weeks

  14. Number of participants with AEs, imAEs, and SAEs leading to dose modifications or study intervention discontinuation

    Time frame: Up to 226 weeks

  15. Number of participants with AEs leading to death

    Time frame: Up to 226 weeks

07

Study locations

1 of 1 sites recruiting
  • GSK Investigational Site
    Jinan, Shandong 250117, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Mar 2030, 52 months after the start.

Of 139 phase 2 interventional studies under Endometrial Neoplasms, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 115. This study's planned 52 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2025
First posted
Aug 7, 2025
StartActual
Nov 27, 2025
Primary completionEst.
Mar 31, 2030
CompletionEst.
Mar 31, 2030
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07108270
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Nov 27, 2025
Primary completion
Mar 31, 2030 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Dec 22, 2025

Study contacts

US GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
877-379-3718
EU GSK Clinical Trials Call Center
Contact
GSKClinicalSupportHD@gsk.com
+44 (0) 20 89904466

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dostarlimab · Carboplatin · Paclitaxel

Start the discussion